NCT01682070已完成2 期
A Randomized, Double-blind, Placebo-controlled Study to Determine Safety, Tolerability and the Optimal Effective Dose of SUBLIVAC FIX Phleum Pratense in Patients With Allergic Rhinitis/Rhinoconjunctivitis Caused by Grass Pollen
HAL Allergy45 个研究点 分布在 2 个国家目标入组 266 人开始时间: 2012年9月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 266
- 试验地点
- 45
- 主要终点
- Nasal Provocation Test (NPT)
研究概览
简要总结
The aim of the study is to determine the optimal effective dose of SUBLIVAC FIX Phleum pratense based on reduction of upper airways reactivity after 5 months of treatment with different dosages of SUBLIVAC FIX Phleum pratense compared to placebo. Furthermore, safety and tolerability will be assessed by the number of related Adverse Events of different dosages of SUBLIVAC FIX Phleum pratense compared to placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent
- •Age ≥ 18 ≤ 60 years
- •Allergic rhinitis/rhinoconjunctivitis related to grass pollen with or without concomitant mild to moderate persistent asthma
- •FEV1 > 70% for patients with a history of asthma, FEV > 70% or PEF > 80% for patients without a history of asthma
- •A positive SPT (mean wheal diameter ≥ 3mm compared to negative control and negative control should be negative) for grass pollen assessed within 1 year before randomization.
- •Positive serum specific anti-grass IgE-test (> 0.7 U/mL)
- •A positive TNPT for grass pollen at screening (Lebel score ≥ 6) at ≤10,000 AU/mL
排除标准
- •Patients with (expected) clinically relevant symptoms during the course of the trial due to concomitant sensitization i.e. positive SPT (mean wheal diameter ≥ 3mm) to allergens other than grass pollen
- •Patients sensitized to pets should not be included if they are regularly exposed to pets and are symptomatic upon exposure to pets
- •Completed immunotherapy (SCIT or SLIT) with grass pollen allergens within the past 5 years
- •Completed unsuccessful specific immunotherapy in the past
- •Vaccination within one week before start of therapy or during the initiation phase
- •Anti-IgE therapy within the 6 months prior to inclusion and during the study
- •Severe immune disorders (including auto-immune diseases) and/or diseases requiring immunosuppressive drugs
- •Active malignancies or any malignant disease during the previous 5 years
- •Severe uncontrolled diseases that could increase the risk for patients participating in the study, including but not limited to: cardiovascular insufficiency, any severe or unstable lung diseases, endocrine diseases, clinically significant renal or hepatic diseases, or haematological disorders
- •Active inflammation or infection of the target organs (nose, eyes or lower airways) at the start of the study
- •Moderate to severe nasal obstructive diseases that preclude a TNPT (septal deviation, nasal polyps, recent nasal surgery, etc.)
- •Diseases with a contraindication for the use of Adrenaline (e.g. hyperthyroidism, glaucoma)
- •Use of systemic steroids within 4 weeks before start of the study and during the study
- •Treatment with systemic and local β-blockers
- •Participation in a clinical study with a new investigational drug within the last 3 months or for a biological within the last 6 months prior to or during the study
- •Pregnancy, lactation or inadequate contraceptive measures for women of child-bearing age (adequate contraceptive measures will be the use of a contraceptive device or -pill)
- •Alcohol, drug or medication abuse within the past year
- •Any clinically significant abnormal laboratory parameter at screening
- •Lack of cooperation or compliance
- •Severe psychiatric, psychological, or neurological disorders
- •Patients who are employees of the institution or 1st grade relatives or partners of the investigator
结局指标
主要结局
Nasal Provocation Test (NPT)
时间窗: 5 months
Number of related AEs
时间窗: First ten days of study medication intake
次要结局
- Serum specific immunoglobulin levels (IgE, IgG, IgG4)(5 months)
- Number of local and systemic reactions(Duration of study medication intake (approximately 5 months))
- Peak Nasal Inspiratory Flow (PNIF)(5 months)
研究者
研究点 (45)
Loading locations...
相似试验
已完成
2 期
SUBLIVAC FIX Birch Dose Tolerability/Dose Range FindingAllergic RhinitisAllergic RhinoconjunctivitisNCT01639768HAL Allergy270
已完成
3 期
SUBLIVAC FIX Birch Phase III Short-term EfficacyBirch Pollen Induced Rhinitis/RhinoconjunctivitisNCT02231307HAL Allergy406
已完成
2 期
A Study to Evaluate Efficacy and Safety of Tiotropium in Children 6 to 11 Years Old With Moderate AsthmaAsthmaNCT01383499Boehringer Ingelheim101
已完成
1 期
Evaluation of the Safety and Potential Therapeutic Effects of Cordstem-ST in Patients With Cerebral InfarctionCerebral InfarctionNCT02378974CHABiotech CO., Ltd18
已完成
2 期
A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative ColitisUlcerative ColitisNCT01620255Shire357